AHK-Cu has promising laboratory research involving human hair follicles and dermal papilla cells, but it has not been shown in a controlled human clinical trial to regrow hair.
In the main direct study, researchers found that AHK-Cu stimulated the elongation of isolated human hair follicles ex vivo and increased dermal papilla cell proliferation in vitro.1
Those findings help explain why AHK-Cu has become an ingredient of interest in hair and scalp formulas. But they don't establish that applying an AHK-Cu serum to the scalp will increase hair count, reverse hair loss or produce visible regrowth in people.
So instead of treating AHK-Cu as either a proven hair-growth treatment or an ingredient with no meaningful research behind it, let's look at what has actually been studied — and where the evidence stops.
This article reviews published research for educational purposes and isn't medical advice.
AHK-Cu Hair Growth Evidence at a Glance
| Question | What the Research Shows |
|---|---|
| Has AHK-Cu been studied in human hair follicles? | Yes. Isolated human hair follicles were studied ex vivo.1 |
| Did AHK-Cu affect follicle growth? | AHK-Cu stimulated hair-follicle elongation under the laboratory conditions used in the study.1 |
| Did AHK-Cu affect dermal papilla cells? | It increased cultured dermal papilla cell proliferation in vitro.1 |
| Has topical AHK-Cu been proven to regrow hair in people? | No controlled human clinical trial has established that outcome. |
| Is AHK-Cu clinically proven to treat hair loss? | No. The direct evidence remains primarily experimental rather than clinical.2 |
| Is there a clinically established AHK-Cu concentration or timeline? | No. Laboratory concentrations cannot be converted directly into an optimal topical percentage or consumer-use timeline. |
What Is AHK-Cu?
AHK-Cu is a copper-binding tripeptide.
The letters AHK refer to the three amino acids that make up the peptide sequence:
- A: alanine
- H: histidine
- K: lysine
The “Cu” refers to copper.
In the scientific literature, AHK-Cu may also be written as L-alanyl-L-histidyl-L-lysine-Cu2+.1
AHK-Cu belongs to the broader family of copper-binding peptides. It is closely related to GHK-Cu, but the two are different peptide sequences and the research performed on one should not automatically be applied to the other.
For the structural and evidence differences between the two peptides, see our AHK-Cu vs. GHK-Cu guide.
Why Is AHK-Cu Studied for Hair?
Most of the direct interest in AHK-Cu and hair comes from research involving the hair follicle and dermal papilla cells.
Dermal papilla cells are specialized cells located at the base of the hair follicle. They participate in signaling involved in follicle development and hair growth, which is why they're commonly used in experimental hair research.
In 2007, Pyo and colleagues studied the effect of AHK-Cu on isolated human hair follicles and cultured human dermal papilla cells.1
A 2026 review of short peptides for hair loss still points to that study as the key direct AHK-Cu hair-follicle evidence while also highlighting a broader limitation in peptide hair research: laboratory findings currently outnumber well-controlled human clinical trials.2
What Did the Main AHK-Cu Hair Study Find?
The 2007 study examined AHK-Cu using two related but different experimental models:
- isolated human hair follicles studied outside the body; and
- cultured human dermal papilla cells studied in the laboratory.1
Both models are useful for understanding biology, but neither is the same as testing a finished AHK-Cu hair product on people.
AHK-Cu and Human Hair Follicles
The researchers exposed isolated human hair follicles to AHK-Cu at concentrations ranging from 10-12 to 10-9 M.
AHK-Cu stimulated hair-follicle elongation under those experimental conditions.1
This is meaningful because the experiment used actual human hair follicles.
But the follicles had been removed from the body and maintained in laboratory culture. This type of experiment is described as ex vivo.
So the study involved human tissue, but it was not a human clinical hair-growth trial.
No participants applied AHK-Cu to their scalp and then had outcomes such as hair count, density, shedding or visible regrowth measured.
AHK-Cu and Dermal Papilla Cells
The researchers also tested AHK-Cu on cultured human dermal papilla cells.
AHK-Cu increased dermal papilla cell proliferation in vitro.1
In simple terms, more of the cultured cells were multiplying under the experimental conditions.
That is biologically interesting because dermal papilla cells play an important role in follicle signaling. But increased cell proliferation in a laboratory model does not automatically mean that applying AHK-Cu to a human scalp will increase hair density.
Several unanswered steps sit between those two outcomes, including:
- stability of the finished formulation;
- penetration through the scalp;
- delivery to follicular structures;
- the amount that reaches the target tissue;
- the underlying cause of hair loss; and
- frequency and duration of use.
Those questions have not been resolved in a controlled human AHK-Cu hair-growth trial.
Did AHK-Cu Reduce Dermal Papilla Cell Apoptosis?
This part of the study needs careful interpretation.
The researchers examined apoptosis, a form of programmed cell death.
AHK-Cu treatment changed several apoptosis-related markers. At 10-9 M, the Bcl-2/Bax ratio increased, while levels of cleaved caspase-3 and PARP decreased.1
Those molecular changes are consistent with changes in cell-survival signaling.
However, the actual reduction in the number of apoptotic dermal papilla cells was not statistically significant.1
That's why a statement such as “AHK-Cu prevents dermal papilla cell death” goes further than the experiment demonstrated.
A more accurate interpretation is that AHK-Cu affected several apoptosis-related markers, while the measured reduction in apoptotic cells itself did not reach statistical significance.
What Do Ex Vivo and In Vitro Mean?
These terms are important when reading AHK-Cu hair-growth claims.
Ex Vivo
Ex vivo means living tissue has been removed from the body and studied under controlled conditions.
The whole human hair follicles in the AHK-Cu study were evaluated ex vivo.1
In Vitro
In vitro generally refers to experiments carried out in a controlled laboratory environment, such as cultured cells.
The dermal papilla cell portion of the study was performed in vitro.1
Neither term means researchers tested a finished AHK-Cu scalp product in living participants.
This distinction matters because describing the study simply as a “human hair-growth trial” would make the evidence sound stronger than it is.
Does AHK-Cu Regrow Hair in People?
That has not been established.
The existing research provides a biological reason to investigate AHK-Cu further, but controlled human evidence has not established that topical AHK-Cu:
- regrows lost hair;
- increases visible hair density;
- increases hair count;
- reverses follicle miniaturization;
- prevents future hair loss; or
- treats a diagnosed form of alopecia.
The 2026 review of short peptides for hair loss describes peptide-based approaches as promising while also emphasizing limitations such as a shortage of clinical trials, model-system constraints, biological variability and delivery challenges.2
This doesn't mean AHK-Cu has no value as a cosmetic hair ingredient.
It means the strength of the claim should match the strength of the evidence.
Does AHK-Cu Help With Hair Loss?
Hair-follicle activity and treatment of a hair-loss condition are not automatically the same thing.
AHK-Cu has experimental evidence involving follicles and dermal papilla cells, but it has not been clinically established as a treatment for a specific form of hair loss.
Androgenetic Alopecia
Androgenetic alopecia, commonly called male or female pattern hair loss, involves progressive follicle miniaturization influenced by genetics and androgen signaling.
There is no established controlled human trial showing that AHK-Cu treats androgenetic alopecia.
Telogen Effluvium
Telogen effluvium occurs when more hairs than usual shift into the resting and shedding phases of the hair cycle.
AHK-Cu has not been clinically established as a treatment for telogen effluvium.
Alopecia Areata
Alopecia areata is an autoimmune form of hair loss.
AHK-Cu has not been established as a treatment for alopecia areata.
Sudden, patchy, unexplained or persistent hair loss should be evaluated based on its underlying cause rather than assuming one cosmetic peptide addresses every type of hair loss.
Does AHK-Cu Block DHT?
There is no direct evidence establishing AHK-Cu as a DHT blocker.
The main AHK-Cu study examined follicle elongation, dermal papilla cell proliferation and apoptosis-related markers. It did not test AHK-Cu as a 5-alpha-reductase inhibitor, androgen-receptor blocker or another anti-androgen treatment.1
That distinction matters for pattern hair loss.
An ingredient being studied for follicle biology isn't automatically acting through the same pathway as a treatment that directly affects androgen signaling.
Does AHK-Cu Extend the Anagen Phase?
You may see AHK-Cu described as a peptide that keeps hair in the anagen, or active-growth, phase for longer.
The direct research is narrower than that claim.
The 2007 study found increased elongation of isolated human hair follicles during the experimental period.1
It did not follow people over multiple hair cycles to determine whether topical AHK-Cu extends anagen duration on a living scalp.
So the evidence supports saying that AHK-Cu stimulated follicle elongation ex vivo.
It does not establish that AHK-Cu clinically prolongs the anagen phase in people.
AHK-Cu vs. GHK-Cu for Hair
AHK-Cu and GHK-Cu are related copper-binding tripeptides, but they are not the same molecule.
AHK-Cu has direct experimental hair-follicle research from the 2007 Pyo study.1
That does not prove AHK-Cu is clinically better than GHK-Cu for hair. There is no head-to-head human clinical trial establishing superior hair-growth outcomes for one peptide over the other.
For the structural differences, evidence base and practical comparison, see our AHK-Cu vs. GHK-Cu guide.
What Concentration of AHK-Cu Was Studied?
The main follicle study reported effects at AHK-Cu concentrations between 10-12 and 10-9 M.1
Those are laboratory concentrations. They should not be converted directly into percentages used in consumer scalp serums.
An isolated follicle maintained in culture is exposed very differently from a peptide applied to the surface of the scalp.
There is currently no clinically established topical AHK-Cu percentage proven to produce the best hair-growth result.
For concentration, percentage and dose-related questions, see our AHK-Cu dosage guide.
How Long Does AHK-Cu Take to Work for Hair?
Human research does not establish an AHK-Cu hair-growth timeline.
You may see timelines such as four weeks, eight weeks, three months or six months repeated online. Those timelines do not come from a controlled human AHK-Cu hair-growth trial.
Hair biology is slow in general, but that fact cannot be used to manufacture a specific AHK-Cu response timeline.
Until clinical studies measure outcomes such as hair count, density and visible regrowth in people using topical AHK-Cu, there is no validated answer to exactly how many weeks or months AHK-Cu takes to “work.”
What We Still Don't Know About AHK-Cu and Hair
The most useful way to interpret AHK-Cu is to separate the promising experimental findings from the unanswered clinical questions.
Human research is still needed to determine:
- whether topical AHK-Cu increases hair count;
- whether it increases visible hair density;
- whether it affects follicle miniaturization;
- which types of hair loss, if any, respond;
- the optimal topical concentration;
- the ideal application frequency;
- how efficiently AHK-Cu penetrates the human scalp;
- how much reaches follicular structures;
- how long use would need to continue;
- whether any effects persist after use stops;
- how AHK-Cu compares directly with GHK-Cu; and
- whether finished commercial formulations reproduce the effects seen in laboratory research.
Those aren't minor details. They're the difference between an ingredient with interesting biological research and a clinically established hair-loss treatment.
For a broader look at peptide ingredients discussed in relation to hair, see our guide to peptides for hair growth.
AHK-Cu Hair Growth FAQ
Does AHK-Cu actually grow hair?
AHK-Cu stimulated the elongation of isolated human hair follicles in an ex vivo study, but it has not been established in a controlled human clinical trial to regrow hair on the scalp.1
Is AHK-Cu clinically proven for hair growth?
No. The main direct evidence comes from isolated human hair follicles and cultured dermal papilla cells rather than clinical trials of people using topical AHK-Cu.1 A 2026 review also highlights the continuing shortage of clinical trials in peptide-based hair research.2
What does AHK-Cu do to dermal papilla cells?
In the 2007 study, AHK-Cu increased cultured dermal papilla cell proliferation and changed several apoptosis-related markers. The measured reduction in apoptotic cell numbers itself was not statistically significant.1
Does AHK-Cu block DHT?
There is no direct evidence establishing AHK-Cu as a DHT blocker or anti-androgen. The main AHK-Cu study did not test DHT inhibition.1
Does AHK-Cu help with hair loss?
AHK-Cu has experimental evidence involving human follicles and dermal papilla cells, but it has not been clinically established as a treatment for androgenetic alopecia, telogen effluvium, alopecia areata or another specific hair-loss condition.
Is AHK-Cu better than GHK-Cu for hair?
That has not been demonstrated in a head-to-head human clinical trial. The two peptides have different research histories, and evidence from one should not automatically be assigned to the other.
How long does AHK-Cu take to work?
There is no clinically established AHK-Cu hair-growth timeline. Specific timelines circulated online are not supported by controlled human AHK-Cu hair-growth trials.
AHK-Cu Hair Growth: The Bottom Line
AHK-Cu has legitimate hair-related laboratory research behind it.
In the main direct study, AHK-Cu stimulated the elongation of isolated human hair follicles and increased cultured dermal papilla cell proliferation under experimental conditions. It also changed several markers related to cell-survival signaling.1
But the evidence stops well short of proving that a topical AHK-Cu product regrows hair in people.
There is currently no established controlled human trial showing that AHK-Cu treats androgenetic alopecia, telogen effluvium, alopecia areata or another form of hair loss.
AHK-Cu is therefore better described as a copper peptide with promising experimental hair-follicle research than as a clinically proven hair-growth treatment.
When evaluating an AHK-Cu hair claim, ask three questions:
- Was the research performed on AHK-Cu specifically?
- Was it tested in people or only in follicles and cultured cells?
- Was a finished topical product actually studied?
Those questions make it much easier to separate promising biology from claims that go beyond the current evidence.
References
- Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. doi:10.1007/BF02978833. PMID: 17703734. View study.
- Fan C, Chen Y, Huang Q, Ou WY, Zhang C, et al. Overview of Short Peptides for Hair Loss. Biomedicines. 2026;14(4):864. doi:10.3390/biomedicines14040864. PMID: 42072405. View review.
